Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia

Dinaciclib enhances NK-cell activity against leukemia cells in preclinical AML models. Enhanced NK-cell activation by dinaciclib-treated AML is associated with downregulation of inhibitory NK ligand HLA-E on leukemia cells.

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: Yun, Hyun Don, Schirm, Dawn K., Felices, Martin, Miller, Jeffrey S., Eckfeldt, Craig E.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2019
Assuntos:
Stimulus Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6712524/
https://ncbi.nlm.nih.gov/pubmed/31416822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000064
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares